| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CLINICAL STUDY |
1 Centre for Diabetes and Endocrinology, Barnsley NHS Foundation Trust Hospital, Barnsley, United Kingdom, 2 Department of Cardiology, Royal Hallamshire Hospital, Sheffield, United Kingdom and 3 Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, United Kingdom
(Correspondence should be addressed to T H Jones who is now at Centre for Diabetes and Endocrinology, Barnsley NHS Foundation Trust Hospital, Gawber Road, Barnsley S75 2EP, United Kingdom; Email: hugh.jones{at}nhs.net)
Objective: Serum testosterone levels are known to inversely correlate with insulin sensitivity and obesity in men. Furthermore, there is evidence to suggest that testosterone replacement therapy reduces insulin resistance and visceral adiposity in type 2 diabetic men. Adipocytokines are hormones secreted by adipose tissue and contribute to insulin resistance. We examined the effects of testosterone replacement treatment on various adipocytokines and C-reactive protein (CRP) in type 2 diabetic men.
Design: Double-blinded placebo-controlled crossover study in 20 hypogonadal type 2 diabetic men. Patients were treated with testosterone (sustanon 200 mg) or placebo intramuscularly every 2 weeks for 3 months in random order followed by a washout period of 1 month before the alternate treatment phase.
Methods: Leptin, adiponectin, resistin, tumour necrosis factor-
(TNF-), interleukin (IL)-6 and CRP levels were measured before and after each treatment phase. Body mass index (BMI) and waist circumference were also recorded.
Results: At baseline, leptin levels significantly correlated with BMI and waist circumference. There was a significant inverse correlation between baseline IL-6 and total testosterone (r=–0.68; P=0.002) and bioavailable testosterone levels (r=–0.73; P=0.007). CRP levels also correlated significantly with total testosterone levels (r=–0.59; P=0.01). Testosterone treatment reduced leptin (–7141.9 ± 1461.8 pg/ml; P=0.0001) and adiponectin levels (–2075.8 ± 852.3 ng/ml; P=0.02). There was a significant reduction in waist circumference. No significant effects of testosterone therapy on resistin, TNF-, IL-6 or CRP levels were observed.
Conclusion: Testosterone replacement treatment decreases leptin and adiponectin levels in type 2 diabetic men. Moreover, low levels of testosterone in men are associated with pro-inflammatory profile, though testosterone treatment over 3 months had no effect on inflammatory markers.
This article has been cited by other articles:
|
|
 |
|
  R D Stanworth, D Kapoor, K S Channer, and T H Jones Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes Eur. J. Endocrinol., December 1, 2008; 159(6): 739 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-S. Youn, N. Kloting, J. Kratzsch, N. Lee, J. W. Park, E.-S. Song, K. Ruschke, A. Oberbach, M. Fasshauer, M. Stumvoll, et al. Serum Vaspin Concentrations in Human Obesity and Type 2 Diabetes Diabetes, February 1, 2008; 57(2): 372 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Seeger, M. Ziegelmeier, A. Bachmann, U. Lossner, J. Kratzsch, M. Bluher, M. Stumvoll, and M. Fasshauer Serum Levels of the Adipokine Vaspin in Relation to Metabolic and Renal Parameters J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 247 - 251. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
